In PitNETs expressing DRD2, modulation of P-FLNA might suggest new pharmacological strategies to overcome drug resistance and P-FLNA might represent a new molecular biomarker for tumor responsiveness to DAs. This evidence concerns the gene DRD2 and neoplasm.